Diagnosis

If your doctor suspects cholangiocarcinoma, he or she may have you undergo one or more of the following tests:

  • Liver function tests. Blood tests to measure your liver function can give your doctor clues about what's causing your signs and symptoms.
  • Tumor marker test. Checking the level of cancer antigen (CA) 19-9 in your blood may give your doctor additional clues about your diagnosis. CA 19-9 is a protein that's overproduced by bile duct cancer cells.

    A high level of CA 19-9 in your blood doesn't mean you have bile duct cancer, though. This result can also occur in other bile duct diseases, such as bile duct inflammation and obstruction.

  • A test to examine your bile duct with a small camera. During endoscopic retrograde cholangiopancreatography (ERCP), a thin tube equipped with a tiny camera is passed down your throat and through your digestive tract to your small intestine. The camera is used to examine the area where your bile ducts connect to your small intestine. Your doctor may also use this procedure to inject dye into the bile ducts to help them show up better on imaging tests.
  • Imaging tests. Imaging tests can help your doctor see any abnormalities in your internal organs that may indicate cholangiocarcinoma. Techniques used to diagnose bile duct cancer include computerized tomography (CT) scans and magnetic resonance imaging (MRI) combined with magnetic resonance cholangiopancreatography (MRCP). MRCP is increasingly being used as a noninvasive alternative to ERCP. It offers 3-D images without the need for a dye to enhance the images.
  • A procedure to remove a sample of tissue for testing. A biopsy is a procedure to remove a small sample of tissue for examination under a microscope.

    If the suspicious area is located very near where the bile duct joins the small intestine, your doctor may obtain a biopsy sample during ERCP. If the suspicious area is within or near the liver, your doctor may obtain a tissue sample by inserting a long needle through your skin to the affected area (fine-needle aspiration). He or she may use an imaging test, such as an endoscopic ultrasound or CT scan, to guide the needle to the precise area.

    How your doctor collects a biopsy sample may influence which treatment options are available to you later. For example, if your bile duct cancer is biopsied by fine-needle aspiration, you will become ineligible for liver transplantation. Don't hesitate to ask about your doctor's experience with diagnosing cholangiocarcinoma. If you have any doubts, get a second opinion.

If your doctor confirms a diagnosis of cholangiocarcinoma, he or she tries to determine the extent (stage) of the cancer. Often this involves additional imaging tests. Your cancer's stage helps determine your prognosis and your treatment options.

April 25, 2017
References
  1. AskMayoExpert. Cholangiocarcinoma. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2016.
  2. Feldman M, et al. Tumors of the bile ducts, gallbladder and ampulla. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed Feb. 22, 2016.
  3. Rizvi S, et al. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion. 2014;89:216.
  4. Zaydfudim VM, et al. Hilar cholangiocarcinoma. Surgical Oncology Clinics of North America. 2014;23:247.
  5. Riggin EA. Allscipts EPSi. Mayo Clinic, Rochester, Minn. Oct. 27, 2016.
  6. Brown AY. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Nov. 3, 2016.
  7. Smoot RL (expert opinion). Mayo Clinic, Rochester, Minn. March 23, 2017.
  8. Choi J, et al. Aspirin use and the risk of cholangiocarcinoma. Hepatology. 2016;64:785.
  9. Doherty B, et al. Update on the diagnosis and treatment of cholangiocarcinoma. Current Gastroenterology Reports. 2017;19:2.
  10. Borad MJ, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PloS Genetics 2014;10:e1004135. http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1004135. Accessed Feb. 27, 2017.
  11. Barbara Woodward Lips Patient Education Center. Surgery on the extrahepatic bile duct, duodenum, papilla, or pancreas. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2012.
  12. Merck Manual Professional Version. Tumors of the gallbladder and bile ducts. https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/gallbladder-and-bile-duct-disorders/tumors-of-the-gallbladder-and-bile-ducts#v902250. Accessed Feb. 28, 2017.
  13. Bergquist JR, et al. Implications of CA19-9 elevation for survival, staging and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. Journal of Surgical Oncology. 2016;114:475.